Waxman Report Showing FDA Pre-emption Split May Alter Legal Debate
This article was originally published in The Tan Sheet
Executive Summary
A report from influential House leader Henry Waxman exposes a rift between senior FDA staff and the agency's Office of Chief Counsel that could help the plaintiff in the FDA pre-emption case that has reached the Supreme Court